Status:
COMPLETED
A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes
Lead Sponsor:
Diabetes Care Center
Collaborating Sponsors:
Novo Nordisk A/S
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study that when studies using our method of dosing adjustments driven by continuous glucose monitoring and because of the less variable glycemic effect of insulin detemir, insulin ...
Detailed Description
Todate, most studies have compared insulin detemir and glargine to NPH and not to each other. Depending of their design, these studies have shown both insulins lower the fasting glucose, A1c, the inci...
Eligibility Criteria
Inclusion
- Type 2 Diabetes
- Currently on a basal insulin, that is, NPH, glargine or detemir
- Capable of self monitoring glucose \>4/day
- Previously complaint with clinical recommendations
- Subject may be on oral antiglycemic medications but no change in treatment is permitted during study.
Exclusion
- Hb A1c \>9.0%
- Urinary ketosis
- Currently or expected alteration in insulin sensitivity such as major surgery, infection, renal failure (creatine \>1.5 mg/dL) glucocorticoid treatment, recent (within 2 weeks) serious hypoglycaemic episode (requires assistance of another)
- Currently participating in another clinical trial
- Known or suspected allergy to insulin glargine or detemir
- Using other insulins, such as, bolus insulin or premixed insulin
- Sight or hearing impaired
- Pregnancy oor nursing of the intention of becoming pregnant or not using adequate contraceptive measures.
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2007
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00457093
Start Date
October 1 2006
End Date
May 1 2007
Last Update
November 18 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Diabetes Care Center
Salinas, California, United States, 93901